A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
暂无分享,去创建一个
S. Voloshin | M. Mauro | N. Chaudhri | Dong-Wook Kim | P. Coutre | P. Aimone | J. Apperley | Timothy P Hughes | S. Saussele | M. Annunziata | L. Fogliatto | K. Sasaki | L. Chee | S. Quenet | Y. Minami | A. Turkina | Jordi Cortés | A. Abdo | Delphine | E. Lomaia | C. Boquimpani | Dennis Dong Hwan Kim | Alex Allepuz | T. Hughes | A. Allepuz | D. Kim